The Business Of Biotech Podcast
-
BoB In South Florida: Anthony Japour, M.D., iTolerance
10/16/2025
On this week's episode of the Business of Biotech, Anthony Japour, M.D., CEO at iTolerance, talks about his work as a physician treating infectious diseases, his CEO role in diagnostics at the height of the COVID-19 pandemic, what he learned working as a medical director at a large CRO, and iTolerance's work toward a cure for Type 1 diabetes that doesn't require chronic immunosuppression.
-
BoB In South Florida: Daniel Teper, NAYA Therapeutics
10/9/2025
In this week's episode of the Business of Biotech -- part two in a four-part series recorded in-person at Catalyst Pharmaceuticals' Miami headquarters -- we're speaking with Daniel Teper, an entrepreneur and most recently, founder and CEO at NAYA Therapeutics.
-
BoB In South Florida: Raquel Cabo, Miami Biotech Collective
10/2/2025
The Business of Biotech is on location in Miami this week! For the first episode in this four-part series on the biotech scene in South Florida, Raquel Cabo, Founder and President of the Miami Biotech Collective, talks about her experiences as a member of the founding team at Ovid Therapeutics, why South Florida needed an organization to connect regional drug developers, and more.
-
The Business Case For Health Economics And Outcomes Research With ISPOR's Rob Abbott
9/26/2025
On this week's episode of the Business of Biotech, Rob Abbott, CEO of ISPOR, explains how startup and early-stage clinical drug development companies benefit from conducting health economics and outcomes research (HEOR), and not just with patients and commercial payers.
-
Cannabinoid And Psychedelic Combinations With Incannex Healthcare's Joel Latham
9/19/2025
On this week's Business Of Biotech episode, Joel Latham, President and CEO at Incannex Healthcare, talks about developing cannabinoid and psychedelic combination therapies for conditions as diverse as sleep apnea, rheumatoid arthritis, and generalized anxiety disorder.
-
Dye Drug Conjugates For Cancer With Lahjavida's Lyle Small
9/11/2025
On this week's Business Of Biotech episode, Lyle Small, Founder and CEO at Lahjavida, a dye drug conjugate start-up, talks about creating the famous color-changing technology that turned the mountains blue on cold Coors Light beer cans, to launching a dye-drug conjugate startup developing targeted cancer therapies.
-
Investing In The Biostack With Modi Ventures' Sahir Ali, Ph.D.
9/4/2025
On the Business of Biotech this week, Sahir Ali, Ph.D., founder and general partner at Modi Ventures, a family office investing at the intersection of technology and biology, talks about adapting the Markowitz model to improve returns and balance risk, his concept of the "biostack" for making direct investments into life sciences companies, and the revolutionary potential of scientific super intelligence.
-
Improving Cardiovascular Outcomes With Immediate Therapeutics' Atul Deshpande, Ph.D.
8/27/2025
On this week's Business Of Biotech episode, Atul Deshpande, Ph.D., CEO at Immediate Therapeutics, talks about partnering with American cities to conduct clinical trials during ambulance rides to the hospital, with the goal of preserving heart function and reducing mortality related to acute cardiovascular events, including heart attacks.
-
Building A Biotech Incubator And Accelerator With Swiss Rockets Founder And CEO Vladimir Cmiljanovic, Ph.D.
8/21/2025
On this week's episode, ex-handballer Vladimir Cmiljanovic, Ph.D., Founder and CEO at Swiss Rockets, talks about co-discovering bimiralisib with his sister Natasa Cmiljanovic, Ph.D. (and COO at Swiss Rockets), losing his company to a hostile takeover, buying the company back, and building out Swiss Rockets as an incubator with manufacturing capabilities and shared scientific expertise.
-
Biotech Product Partnership with Coya Therapeutics' Arun Swaminathan, Ph.D. and Dr. Reddy's Milan Kalawadia
8/13/2025
On this week's Business Of Biotech episode, Milan Kalawadia, CEO, North America, Dr. Reddy's Laboratories, and Arun Swaminathan, Ph.D., CEO, Coya Therapeutics discuss their unique partnership to develop COYA 302, a novel dual-mechanism immunotherapy for the treatment of ALS.